This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by von Eckardstein, S. Articles by Nieschlag, E. Search for Related Content PubMed PubMed Citation Articles by von Eckardstein, S. Articles by Nieschlag, E.

Treatment of Male Hypogonadism With Testosterone Undecanoate Injected at Extended Intervals of 12 Weeks: A Phase II Study

From the Institute of Reproductive Medicine of the University, D-48129 Münster, Germany

Correspondence to: Dr E. Nieschlag, FRCP, Institute of Reproductive Medicine of the University, Domagkstrasse 11, D-48129 Münster, Germany (e-mail: nieschl{at}uni-muenster.de ).

This paper reports the result of an open-label, nonrandomized clinical trial investigating the efficacy and safety of an injectable preparation of testosterone undecanoate (TU) dissolved in castor oil and given over a 3.2-year period. In a previous study we demonstrated that injections of TU every 6 weeks resulted in satisfactory substitution but a tendency toward testosterone accumulation. Here we investigate prolonged TU treatment at extended injection intervals in 7 hypogonadal men. Injections were given at gradually increasing intervals between the fifth and 10th injection, and from then on every 12 weeks. Steady state kinetics were obtained after the 13th injection. Well-being, sexual activity, clinical chemistry, prostate volume, and prostate-specific antigen (PSA) and serum hormone levels were monitored. Patients were clinically well-adjusted throughout the study. Before the next injection, testosterone, dihydrotestosterone, and estradiol levels were mostly within the normal range and showed a tendency to decrease with increasing injection intervals. Body weight, hemoglobin, serum lipids, PSA, and prostate volume did not change significantly during the 3.2 years of treatment. PSA levels were always within the normal limit. Maximal testosterone levels during steady state kinetics were measured after 1 week with 32.0 ± 11.7 nmol/L (mean ± SD). Before the last injection, mean testosterone concentrations were 12.6 ± 3.7 nmol/L. Compared with conventional testosterone enanthate or cypionate treatment requiring injection intervals of 2-3 weeks and resulting in supraphysiological serum testosterone levels, injections of TU at intervals of up to 3 months offer an excellent alternative for substitution therapy of male hypogonadism.

     Key words: Injectable testosterone undecanoate, substitution of male hypogonadism

This article has been cited by other articles:

				E. Mommers, W. M. Kersemaekers, J. Elliesen, M. Kepers, D. Apter, H. M. Behre, J. Beynon, P. M. Bouloux, A. Costantino, H.-P. Gerbershagen, et al. Male Hormonal Contraception: A Double-Blind, Placebo-Controlled Study J. Clin. Endocrinol. Metab., July 1, 2008; 93(7): 2572 - 2580. [Abstract] [Full Text] [PDF]

				M. Zitzmann and E. Nieschlag Androgen Receptor Gene CAG Repeat Length and Body Mass Index Modulate the Safety of Long-Term Intramuscular Testosterone Undecanoate Therapy in Hypogonadal Men J. Clin. Endocrinol. Metab., October 1, 2007; 92(10): 3844 - 3853. [Abstract] [Full Text] [PDF]

				A. Mueller, F. Kiesewetter, H. Binder, M. W. Beckmann, and R. Dittrich Long-Term Administration of Testosterone Undecanoate Every 3 Months for Testosterone Supplementation in Female-to-Male Transsexuals J. Clin. Endocrinol. Metab., September 1, 2007; 92(9): 3470 - 3475. [Abstract] [Full Text] [PDF]

				A. Qoubaitary, C. Meriggiola, C. M. Ng, L. Lumbreras, S. Cerpolini, G. Pelusi, P. D. Christensen, L. Hull, R. S. Swerdloff, and C. Wang Pharmacokinetics of Testosterone Undecanoate Injected Alone or in Combination With Norethisterone Enanthate in Healthy Men J Androl, November 1, 2006; 27(6): 853 - 867. [Abstract] [Full Text] [PDF]

				M.C. Meriggiola, S. Cerpolini, W.J. Bremner, M.T. Mbizvo, K.M. Vogelsong, G. Martorana, and G. Pelusi Acceptability of an injectable male contraceptive regimen of norethisterone enanthate and testosterone undecanoate for men Hum. Reprod., August 1, 2006; 21(8): 2033 - 2040. [Abstract] [Full Text] [PDF]

				J. K. Parsons, H. B. Carter, E. A. Platz, E. J. Wright, P. Landis, and E. J. Metter Serum Testosterone and the Risk of Prostate Cancer: Potential Implications for Testosterone Therapy Cancer Epidemiol. Biomarkers Prev., September 1, 2005; 14(9): 2257 - 2260. [Abstract] [Full Text] [PDF]

				M. C. Meriggiola, A. Costantino, F. Saad, L. D'Emidio, A. M. Morselli Labate, A. Bertaccini, W. J. Bremner, I. Rudolph, M. Ernst, B. Kirsch, et al. Norethisterone Enanthate Plus Testosterone Undecanoate for Male Contraception: Effects of Various Injection Intervals on Spermatogenesis, Reproductive Hormones, Testis, and Prostate J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 2005 - 2014. [Abstract] [Full Text] [PDF]

				M. Schubert, T. Minnemann, D. Hubler, D. Rouskova, A. Christoph, M. Oettel, M. Ernst, U. Mellinger, W. Krone, and F. Jockenhovel Intramuscular Testosterone Undecanoate: Pharmacokinetic Aspects of a Novel Testosterone Formulation during Long-Term Treatment of Men with Hypogonadism J. Clin. Endocrinol. Metab., November 1, 2004; 89(11): 5429 - 5434. [Abstract] [Full Text] [PDF]

				E. Nieschlag, H.M. Behre, P. Bouchard, J.J. Corrales, T.H. Jones, G.K. Stalla, S.M. Webb, and F.C.W. Wu Testosterone replacement therapy: current trends and future directions Hum. Reprod. Update, September 1, 2004; 10(5): 409 - 419. [Abstract] [Full Text] [PDF]

				M. Korbonits, M. Slawik, D. Cullen, R. J. Ross, G. Stalla, H. Schneider, M. Reincke, P. M. Bouloux, and A. B. Grossman A Comparison of a Novel Testosterone Bioadhesive Buccal System, Striant, with a Testosterone Adhesive Patch in Hypogonadal Males J. Clin. Endocrinol. Metab., May 1, 2004; 89(5): 2039 - 2043. [Abstract] [Full Text] [PDF]

				E. L. Rhoden and A. Morgentaler Risks of Testosterone-Replacement Therapy and Recommendations for Monitoring N. Engl. J. Med., January 29, 2004; 350(5): 482 - 492. [Full Text] [PDF]

				M. C. Meriggiola, A. Costantino, S. Cerpolini, W. J. Bremner, D. Huebler, A. M. Morselli-Labate, B. Kirsch, A. Bertaccini, C. Pelusi, and G. Pelusi Testosterone Undecanoate Maintains Spermatogenic Suppression Induced by Cyproterone Acetate Plus Testosterone Undecanoate in Normal Men J. Clin. Endocrinol. Metab., December 1, 2003; 88(12): 5818 - 5826. [Abstract] [Full Text] [PDF]

				G. F. Weinbauer, C.-J. Partsch, M. Zitzmann, S. Schlatt, and E. Nieschlag Pharmacokinetics and Degree of Aromatization Rather Than Total Dose of Different Preparations Determine the Effects of Testosterone: A Nonhuman Primate Study in Macaca fascicularis J Androl, September 1, 2003; 24(5): 765 - 774. [Abstract] [Full Text] [PDF]

				D. J. Handelsman Hormonal Male Contraception--Lessons from the East When the Western Market Fails J. Clin. Endocrinol. Metab., February 1, 2003; 88(2): 559 - 561. [Full Text] [PDF]